HURA - NASDAQ
TuHURA Biosciences, Inc.
$2.27
+9.4%TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
At a Glance
Live SnapshotTuHURA Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
TuHURA Biosciences, Inc. Cash Flow Statement
HURA • NASDAQ
| TuHURA Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||
-30.1M | -21.7M | -29.3M | -9.4M | -7M | -38.3M | -9.1M | -8M | -11.1M | -8.1M | -8.9M | -4.3M | |
71.3K | 116.7K | 177.4K | 373.1K | 380.7K | 32K | 10K | 16.3K | 24.5K | 16.7K | 10.3K | 0.0 | |
6.4M | 2M | 478.9K | 218.3K | 654.5K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-924.5K | 1.6M | 21M | -294.1K | -527.1K | 22.1M | 701K | 569.7K | 685.4K | 524.4K | 3.8M | -31.9K | |
-3.1M | 3.3M | 486.9K | 1.6M | -55K | -2.7M | 487K | 1.1M | 577.5K | -478.4K | -117.3K | 526.5K | |
-27.6M | -14.7M | -7.2M | -7.5M | -6.6M | -18.9M | -7.9M | -6.3M | -9.9M | -8M | -5.1M | -3.9M | |
INVESTING ACTIVITIES | ||||||||||||
-76.1K | -57.9K | -79.2K | -36.3K | -3.3K | -8K | (0.0) | (0.0) | -12.6K | -21K | -16.8K | (0.0) | |
-1.3M | -6M | -1.2M | (0.0) | (0.0) | (972K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.3M | -6.1M | -1.3M | -36.3K | -3.3K | (964K) | (0.0) | (0.0) | -12.6K | -21K | -16.8K | (0.0) | |
FINANCING ACTIVITIES | ||||||||||||
21.9M | 5M | -24.8K | 0.0 | 5.6M | 26.1M | 6.6M | 4.1M | 9.3M | 8.5M | 9.6M | 1.4M | |
617K | 28.6M | 2.7M | -350K | 294.1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-8.4K | (0.0) | (0.0) | (0.0) | -8K | -8K | -8K | -8.4K | -8.4K | -8.4K | -8.4K | -6.3K | |
(0.0) | (0.0) | -24.8K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.6M | -3.8M | 0.0 | 0.0 | 8K | -30K | -25K | 0.0 | 0.0 | 0.0 | 0.0 | -550.1K | |
19.9M | 29.8M | 2.7M | 16.3M | 7M | 26M | 6.6M | 4.1M | 9.2M | 8.5M | 9.6M | 847.8K | |
CASH FLOW SUMMARY | ||||||||||||
-9M | 9M | -10.6M | 8.7M | 477.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
12.7M | 3.7M | 14.3M | 5.5M | 5.1M | 2.4M | 3.7M | 6M | 6.6M | 6.2M | 1.8M | 4.8M | |
3.6M | 12.7M | 3.7M | 14.3M | 5.5M | 10.5M | 2.4M | 3.7M | 6M | 6.6M | 6.2M | 1.8M | |
-27.7M | -14.8M | -12M | -7.5M | -6.6M | -18.9M | -7.9M | -6.3M | 0.0 | -8M | -5.1M | 0.0 |
SEC Filings
HURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 30, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 29, 2026 | 2026 |
Related Guides
Continue your HURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.